Jangaard K A, Stinson D A, Allen A C, Vincer M J
Department of Neonatal Pediatrics, Dalhousie University, Halifax, Nova Scotia.
Paediatr Child Health. 2002 Jan;7(1):13-9. doi: 10.1093/pch/7.1.13.
Inflammation plays an important role in the development of chronic lung disease (CLD), which has become a major cause of morbidity in surviving infants less than 1250 g at birth. The authors hypothesized that the progression of this inflammation and, therefore, the establishment of CLD would be decreased with the use of early prophylactic inhaled corticosteroids. Short, and long term respiratory and neurodevelopmental outcomes were also examined.
A double-blind, randomized placebo controlled trial.
Level-III neonatal intensive care unit.
Sixty infants less than 1250 g at birth, diagnosed with respiratory distress syndrome and requiring ventilatory support at 72 h of age were enrolled in the study.
Infants enrolled received either placebo or beclomethasone diproprionate by a metered dose inhaler, which was used in-line with the ventilator circuit while the infant was ventilated and then via a spacer until 28 days of age.
Thirty infants were given beclomethasone and 30 were given placebo. There were two deaths in each group. Among the surviving infants, the frequency of moderate-to-severe CLD was 17% in each study group. Mean time to extubation was not different for beclomethasone compared with placebo at 16.4 and 12.5 days (P=0.12), respectively. The requirement for intravenous corticosteroids was lower in the beclomethasone-treated group (RR 0.67, 95% CI 0.43 to 1.04), although this difference was not statistically significant. The incidence of growth failure, infection and intraventricular hemmorhage did not differ between the two groups. Long term outcomes were not different with respect to the incidence of respiratory re-admissions, cerebral palsy, developmental delay, blindness or deafness.
Early treatment with inhaled beclomethasone diproprionate did not reduce the incidence of CLD or decrease the duration of mechanical ventilation. The decrease in intravenous corticosteroid use was not statistically significant. Long term outcome was not affected.
炎症在慢性肺病(CLD)的发展过程中起重要作用,CLD已成为出生时体重不足1250克的存活婴儿发病的主要原因。作者推测,使用早期预防性吸入糖皮质激素可减少这种炎症的进展,从而减少CLD的发生。同时还研究了短期和长期的呼吸及神经发育结局。
一项双盲、随机、安慰剂对照试验。
三级新生儿重症监护病房。
60名出生时体重不足1250克、诊断为呼吸窘迫综合征且在72小时龄时需要通气支持的婴儿纳入本研究。
纳入研究的婴儿通过定量吸入器接受安慰剂或二丙酸倍氯米松治疗,在婴儿通气时与呼吸机回路联用,之后通过储雾罐给药至28日龄。
30名婴儿接受二丙酸倍氯米松治疗,30名接受安慰剂治疗。每组各有2例死亡。在存活婴儿中,每个研究组中重度CLD的发生率均为17%。二丙酸倍氯米松组与安慰剂组的平均拔管时间分别为16.4天和12.5天,无差异(P = 0.12)。二丙酸倍氯米松治疗组静脉使用糖皮质激素的需求较低(相对危险度0.67,95%可信区间0.43至1.04),尽管这一差异无统计学意义。两组间生长发育不良、感染和脑室内出血的发生率无差异。在呼吸再入院、脑瘫、发育迟缓、失明或失聪的发生率方面,长期结局无差异。
早期吸入二丙酸倍氯米松治疗并未降低CLD的发生率,也未缩短机械通气时间。静脉使用糖皮质激素减少的差异无统计学意义。长期结局未受影响。